|Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience|
D Vallisa, P Bernuzzi, L Arcaini, S Sacchi, V Callea, R Marasca, ...
Journal of Clinical Oncology 23 (3), 468-473, 2005
|R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana …|
M Federico, S Luminari, A Dondi, A Tucci, U Vitolo, L Rigacci, ...
|Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients|
S Sacchi, HM Kantarjian, S O'Brien, J Cortes, MB Rios, FJ Giles, M Beran, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 1999
|Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.|
KH sacchi s
|Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study|
S Sacchi, L Marcheselli, A Bari, R Marcheselli, S Pozzi, S Luminari, ...
Haematologica 93 (3), 398-404, 2008
|Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients|
S Pozzi, R Marcheselli, S Sacchi, L Baldini, F Angrilli, E Pennese, ...
Leukemia & lymphoma 48 (1), 56-64, 2007
|Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease|
A Tedeschi, G Benevolo, M Varettoni, ML Battista, PL Zinzani, C Visco, ...
Cancer 118 (2), 434-443, 2012
|Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story|
A Bari, L Marcheselli, S Sacchi, R Marcheselli, S Pozzi, P Ferri, E Balleari, ...
Annals of Oncology 21 (7), 1486-1491, 2010
|Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma|
S Sacchi, M Federico, U Vitolo, C Boccomini, D Vallisa, L Baldini, ...
Haematologica 86 (9), 951-958, 2001
|Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population‐based analysis|
S Pozzi, L Marcheselli, A Bari, EV Liardo, R Marcheselli, S Luminari, ...
British journal of haematology 163 (1), 40-46, 2013
|Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study|
G D'arena, PG Gobbi, C Broglia, S Sacchi, G Quarta, L Baldini, E Iannitto, ...
Leukemia & lymphoma 52 (5), 771-775, 2011
|Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre-and post …|
T Tadmor, A Bari, S Sacchi, L Marcheselli, EV Liardo, I Avivi, N Benyamini, ...
haematologica 99 (1), 125, 2014
|Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis|
M Pirani, R Marcheselli, L Marcheselli, A Bari, M Federico, S Sacchi
Annals of Oncology 22 (8), 1845-1858, 2011
|Diagnosis of essential thrombocythemia at platele counts between 400 and 600x10 (9)/L.|
S Sacchi, G Vinci, L Gugliotta, S Rupoli, L Gargantini, V Martinelli, ...
Fondaz Ferrata Storti: Strada Nuova 134, 27100 Pavia Italy: 011 39 0382 …, 2000
|Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab|
S Sacchi, M Federico, G Dastoli, C Fiorani, G Vinci, V Clò, B Casolari
Critical reviews in oncology/hematology 37 (1), 13-25, 2001
|Introduction of rituximab in front‐line and salvage therapies has improved outcome of advanced‐stage follicular lymphoma patients|
S Sacchi, S Pozzi, L Marcheselli, A Bari, S Luminari, F Angrilli, F Merli, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
|Cytogenetic conversion in a case of polycythaemia vera treated with interferon‐alpha|
C Messora, L Bensi, A Vecchi, R Longo, F Giacobbi, P Temperani, ...
British journal of haematology 86 (2), 402-404, 1994
|Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki‐67 and anti‐bromo‐deoxyuridine …|
B Falini, S Canino, S Sacchi, C Ciani, MF Martelli, J Gerdes, H Stein, ...
British journal of haematology 69 (3), 311-320, 1988
|Bcl-2 oncoprotein expression in acute myeloid leukemia|
L Bensi, R Longo, A Vecchi, C Messora, L Garagnani, S Bernardi, ...
Haematologica 80 (2), 98-102, 1995
|Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma|
S Sacchi, S Pozzi, R Marcheselli, M Federico, A Tucci, F Merli, L Orsucci, ...
Cancer 110 (1), 121-128, 2007